Acadia Healthcare Co., Inc.

{
  "main_header": {
    "sid": 1149727,
    "name": "Acadia Healthcare Co., Inc.",
    "stock_name": "Acadia Healthcare Co., Inc.",
    "full_name": "Acadia Healthcare Co., Inc.",
    "name_url": "stocks-analysis/acadia-healthcare-co-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "13.23",
    "chg": -0.22,
    "chgp": "-1.64%",
    "dir": -1,
    "prev_price": "13.45",
    "mcapval": "2,081.49",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US00404A1097",
    "curr_date": "Jan 12",
    "curr_time": "",
    "bse_nse_vol": "4.46 M",
    "exc_status": "Active",
    "traded_date": "Jan 12, 2026",
    "traded_date_str": "2026 01 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/acadia-healthcare-co-inc-1149727-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Acadia Healthcare Adjusts Valuation Amid Declining Profits and Rising Debt Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/acadia-healthcare-upgraded-to-hold-amid-valuation-improvement-despite-ongoing-financial-struggles-3731764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AcadiaHealthcar_mojoScore_3731764.png",
        "date": "2025-11-26 15:53:00",
        "description": "Acadia Healthcare Co., Inc. has recently experienced a score adjustment reflecting a fair valuation classification. This change is influenced by various financial metrics, including a P/E ratio of 8 and a price to book value of 0.69, amidst challenges such as a significant net profit decline and a high debt-equity ratio."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3723412",
        "imagepath": "",
        "date": "2025-11-23 11:12:14",
        "description": "As of 21 November 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 8, significantly lower than the industry average, while the EV to EBITDA ratio is 6.69, indicating a favorable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the Price to Book Value is 0.69, suggesting that the stock is trading below its book value.\n\nIn comparison to its peers, Acadia Healthcare's P/E ratio of 7.69 is notably lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s fair P/E of 32.46, highlighting a potential undervaluation. The company's recent stock performance has been poor, with a year-to-date return of -61.72%, contrasting sharply with the S&P 500's positive return of 12.26% during the same period, which re..."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3689297",
        "imagepath": "",
        "date": "2025-11-11 11:34:35",
        "description": "As of 7 November 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from very expensive to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69, which suggest that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to peers, Acadia's P/E ratio of 8 is significantly lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s P/E of 32.46, indicating that Acadia may not be priced appropriately relative to its competitors. Furthermore, the company's recent performance has been poor, with a year-to-date return of -54.17% compared to the S&P 500's positive return of 14.40%, reinforcing the notion that the stock is overvalued in the current market environment...."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3685101",
        "imagepath": "",
        "date": "2025-11-10 11:16:00",
        "description": "As of 7 November 2025, Acadia Healthcare Co., Inc. has moved from a very expensive to an expensive valuation grade. The company appears to be overvalued based on its current metrics. The P/E ratio stands at 8, significantly lower than the industry average, while the EV to EBITDA ratio is 6.69, indicating a potentially unfavorable valuation compared to peers. Additionally, the Price to Book Value is 0.69, suggesting that the stock is trading below its book value.\n\nIn comparison to its peers, Acadia's P/E ratio of 8 is notably lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s P/E of 32.46, highlighting a stark contrast in valuation. Furthermore, the company's recent performance has been poor, with a year-to-date return of -50.79% compared to the S&P 500's positive return of 14.40%, reinforcing the notion that Acadia is struggling relative to broader market trends...."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3683205",
        "imagepath": "",
        "date": "2025-11-09 11:09:41",
        "description": "As of 7 November 2025, Acadia Healthcare Co., Inc. has moved from a very expensive to an expensive valuation grade. The company appears to be overvalued based on its current metrics. The P/E ratio stands at 8, which is significantly lower than the peer average, while the EV to EBITDA ratio is 6.69, indicating a potential undervaluation compared to industry standards.\n\nIn comparison to its peers, Acadia's P/E ratio is notably lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, both of which are considered attractive. Additionally, Acadia's EV to EBITDA ratio of 6.69 is also lower than DaVita, Inc.'s 7.56, which is classified as risky. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.79% compared to the S&P 500's 14.40%, reinforcing the notion that the stock is overvalued in its current state...."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3673444",
        "imagepath": "",
        "date": "2025-11-05 11:11:48",
        "description": "As of 31 October 2025, Acadia Healthcare Co., Inc. moved from expensive to fair in its valuation grade. The company is currently fairly valued, with a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69. In comparison, Encompass Health Corp. has a significantly higher P/E ratio of 20.94, indicating a more attractive valuation, while DaVita, Inc. has a P/E ratio of 9.71, which is closer to Acadia's valuation.\n\nDespite its fair valuation, Acadia's stock has underperformed relative to the S&P 500, with a year-to-date return of -47.89% compared to the index's positive return of 16.30%. This trend continues over multiple periods, suggesting that while the company's valuation metrics are reasonable, its stock performance has been disappointing...."
      },
      {
        "title": "Acadia Healthcare Co., Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/acadia-healthcares-valuation-grade-changes-from-expensive-to-fair-amid-stock-volatility-3671353",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AcadiaHealthcar_valuationdot_3671353.png",
        "date": "2025-11-04 15:33:33",
        "description": "Acadia Healthcare Co., Inc. has recently adjusted its valuation, with its stock price at $21.31. Over the past year, the company has experienced significant challenges, reflected in a -49.29% return. Key financial metrics indicate a conservative market position compared to peers in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3666206",
        "imagepath": "",
        "date": "2025-11-03 11:17:09",
        "description": "As of 31 October 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from expensive to fair. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69, all of which suggest that the stock is trading at a discount compared to its earnings and asset value.\n\nIn comparison to peers, Acadia's P/E ratio of 8 is significantly lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s attractive P/E of 32.46, indicating that Acadia may be undervalued relative to these industry leaders. Additionally, Acadia's EV to EBITDA of 6.69 is more favorable than DaVita, Inc.'s risky EV to EBITDA of 7.56. Despite these favorable valuation metrics, Acadia has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -45.78% compared to the S&P 500..."
      },
      {
        "title": "Is Acadia Healthcare Co., Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-acadia-healthcare-co-inc-overvalued-or-undervalued-3664341",
        "imagepath": "",
        "date": "2025-11-02 11:10:18",
        "description": "As of 31 October 2025, Acadia Healthcare Co., Inc. has moved from an expensive to a fair valuation grade. Based on the current metrics, the company appears undervalued, with a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69. In comparison to peers, Acadia's P/E ratio is significantly lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, indicating a more attractive valuation relative to its industry counterparts.\n\nDespite the fair valuation, Acadia's stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.78% compared to the index's 16.30%. This stark contrast in performance reinforces the notion that Acadia may be undervalued in the current market environment...."
      }
    ],
    "total": 27,
    "sid": "1149727",
    "stock_news_url": "https://www.marketsmojo.com/news/acadia-healthcare-co-inc-1149727"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Acadia Healthcare Adjusts Valuation Amid Declining Profits and Rising Debt Concerns

2025-11-26 15:53:00

Acadia Healthcare Co., Inc. has recently experienced a score adjustment reflecting a fair valuation classification. This change is influenced by various financial metrics, including a P/E ratio of 8 and a price to book value of 0.69, amidst challenges such as a significant net profit decline and a high debt-equity ratio.

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-23 11:12:14

As of 21 November 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 8, significantly lower than the industry average, while the EV to EBITDA ratio is 6.69, indicating a favorable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the Price to Book Value is 0.69, suggesting that the stock is trading below its book value. In comparison to its peers, Acadia Healthcare's P/E ratio of 7.69 is notably lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s fair P/E of 32.46, highlighting a potential undervaluation. The company's recent stock performance has been poor, with a year-to-date return of -61.72%, contrasting sharply with the S&P 500's positive return of 12.26% during the same period, which re...

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-11 11:34:35

As of 7 November 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from very expensive to expensive. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69, which suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to peers, Acadia's P/E ratio of 8 is significantly lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s P/E of 32.46, indicating that Acadia may not be priced appropriately relative to its competitors. Furthermore, the company's recent performance has been poor, with a year-to-date return of -54.17% compared to the S&P 500's positive return of 14.40%, reinforcing the notion that the stock is overvalued in the current market environment....

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-10 11:16:00

As of 7 November 2025, Acadia Healthcare Co., Inc. has moved from a very expensive to an expensive valuation grade. The company appears to be overvalued based on its current metrics. The P/E ratio stands at 8, significantly lower than the industry average, while the EV to EBITDA ratio is 6.69, indicating a potentially unfavorable valuation compared to peers. Additionally, the Price to Book Value is 0.69, suggesting that the stock is trading below its book value. In comparison to its peers, Acadia's P/E ratio of 8 is notably lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s P/E of 32.46, highlighting a stark contrast in valuation. Furthermore, the company's recent performance has been poor, with a year-to-date return of -50.79% compared to the S&P 500's positive return of 14.40%, reinforcing the notion that Acadia is struggling relative to broader market trends....

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-09 11:09:41

As of 7 November 2025, Acadia Healthcare Co., Inc. has moved from a very expensive to an expensive valuation grade. The company appears to be overvalued based on its current metrics. The P/E ratio stands at 8, which is significantly lower than the peer average, while the EV to EBITDA ratio is 6.69, indicating a potential undervaluation compared to industry standards. In comparison to its peers, Acadia's P/E ratio is notably lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, both of which are considered attractive. Additionally, Acadia's EV to EBITDA ratio of 6.69 is also lower than DaVita, Inc.'s 7.56, which is classified as risky. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.79% compared to the S&P 500's 14.40%, reinforcing the notion that the stock is overvalued in its current state....

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-05 11:11:48

As of 31 October 2025, Acadia Healthcare Co., Inc. moved from expensive to fair in its valuation grade. The company is currently fairly valued, with a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69. In comparison, Encompass Health Corp. has a significantly higher P/E ratio of 20.94, indicating a more attractive valuation, while DaVita, Inc. has a P/E ratio of 9.71, which is closer to Acadia's valuation. Despite its fair valuation, Acadia's stock has underperformed relative to the S&P 500, with a year-to-date return of -47.89% compared to the index's positive return of 16.30%. This trend continues over multiple periods, suggesting that while the company's valuation metrics are reasonable, its stock performance has been disappointing....

Read full news article

Acadia Healthcare Co., Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges

2025-11-04 15:33:33

Acadia Healthcare Co., Inc. has recently adjusted its valuation, with its stock price at $21.31. Over the past year, the company has experienced significant challenges, reflected in a -49.29% return. Key financial metrics indicate a conservative market position compared to peers in the Pharmaceuticals & Biotechnology sector.

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-03 11:17:09

As of 31 October 2025, the valuation grade for Acadia Healthcare Co., Inc. moved from expensive to fair. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69, all of which suggest that the stock is trading at a discount compared to its earnings and asset value. In comparison to peers, Acadia's P/E ratio of 8 is significantly lower than Encompass Health Corp.'s attractive P/E of 20.94 and The Ensign Group, Inc.'s attractive P/E of 32.46, indicating that Acadia may be undervalued relative to these industry leaders. Additionally, Acadia's EV to EBITDA of 6.69 is more favorable than DaVita, Inc.'s risky EV to EBITDA of 7.56. Despite these favorable valuation metrics, Acadia has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -45.78% compared to the S&P 500...

Read full news article

Is Acadia Healthcare Co., Inc. overvalued or undervalued?

2025-11-02 11:10:18

As of 31 October 2025, Acadia Healthcare Co., Inc. has moved from an expensive to a fair valuation grade. Based on the current metrics, the company appears undervalued, with a P/E ratio of 8, a Price to Book Value of 0.69, and an EV to EBITDA of 6.69. In comparison to peers, Acadia's P/E ratio is significantly lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, indicating a more attractive valuation relative to its industry counterparts. Despite the fair valuation, Acadia's stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.78% compared to the index's 16.30%. This stark contrast in performance reinforces the notion that Acadia may be undervalued in the current market environment....

Read full news article

View All News